ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2018
Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- Reported practices and difficulties for preventing emerging highly resistant bacteria in hemodialysis: the PHYDEL survey.GMS hygiene and infection control · 2026Article
- Integrated Analysis of Patient Networks and Plasmid Genomes to Investigate a Regional, Multispecies Outbreak of Carbapenemase-Producing Enterobacterales Carrying Both blaIMP and mcr-9 Genes.The Journal of infectious diseases · 2024Article
- A practical approach to screening for carbapenemase-producing Enterobacterales- views of a group of multidisciplinary experts from English hospitals.BMC infectious diseases · 2024Article
- Limiting the Spread of Multidrug-Resistant Bacteria in Low-to-Middle-Income Countries: One Size Does Not Fit All.Pathogens (Basel, Switzerland) · 2023Review
- An Overview on Phenotypic and Genotypic Characterisation of Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2022Review
- Decrease of carbapenemase-producing Enterobacteriaceae incidence during the first year of the COVID-19 pandemic.The Journal of infection · 2022Article
- Less contact isolation is more in the ICU: con.Intensive care medicine · 2020Article
- Characteristics of Carbapenemase-ProducingFrontiers in microbiology · 2020Article
- Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An infection control programme was implemented in a 21,000-bed multihospital institution for controlling the spread of carbapenemase-producing Enterobacteriaceae (CPE) and glycopeptide-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.